Ionizing Radiation and the Immune Response - Part B

1st Edition, Volume 378 - July 1, 2023
Editors: Lorenzo Galluzzi, Celine Mirjolet
Language: English
Hardback ISBN:
9 7 8 - 0 - 4 4 3 - 1 8 4 3 2 - 1
eBook ISBN:
9 7 8 - 0 - 4 4 3 - 1 8 4 3 3 - 8

Ionizing Radiation and the Immune Response, Part B, Volume 378 reviews the latest knowledge on the immune response induced by ionizing radiations. Specific chapters in this new… Read more

Purchase options

Limited Offer

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code needed.

Institutional subscription on ScienceDirect

Request a sales quote

Ionizing Radiation and the Immune Response, Part B, Volume 378 reviews the latest knowledge on the immune response induced by ionizing radiations. Specific chapters in this new release include NK functions in radio-induced immune response, TRT and immune response, Radio-induced immune response and lipid metabolism, Effect of protons and heavy ions on immune response, Effect of flash therapy and mini beam on immune response, Radio-induced lymphopenia, CT to potentiate radio-induced immune response, Impact of RT on healthy tissues (inflammation), Radio-induced macrophagic response, To use nanoparticles and ionizing radiations to modulate immune response: opinion of the chemist, biologist and clinician, and much more.

Other sections cover the Role of Dendritic cells in radiation-induced immune response, the Relationship between the tumor microenvironment and the efficacy of the radiotherapy/immunotherapy combination, and Biomarkers of radiation induced response to optimize radio-immunotherapy combination.

Cover
Title page
Table of Contents
Series Page
Copyright
Contributors
Dual impact of radiation therapy on tumor-targeting immune responses
References
Chapter One: Radio-induced lymphopenia in the era of anti-cancer immunotherapy
Abstract
1: Introduction
2: Radio-induced lymphopenia (RIL)
3: Dynamics of RIL
4: RIL in the era of immunotherapies
5: How to implement efficient lymphocyte sparing radiotherapy?
6: Conclusion
Acknowledgments
References
Chapter Two: Combining radiotherapy and NK cell-based therapies: The time has come
Abstract
1: Introduction
2: Radiation therapy can improve the NK cell-mediated anti-tumor response
3: Radiation therapy can impair the NK cells anti-tumor response
4: Combining radiotherapy and NK cells targeted therapies to unleash their anti-tumor activity
5: Conclusion
References
Chapter Three: The role of dendritic cells in radiation-induced immune responses
Abstract
1: Introduction
2: Critical DC populations in tumor immune responses
3: Radiation effects on dendritic cells in the treatment field
4: Summary
5: Conclusions
References
Chapter Four: Immunomodulatory effects of targeted radionuclide therapy
Abstract
1: Introduction
2: Background
3: Radiation-induced DNA damage and the cGAS-STING signaling pathway
4: Antitumor immunity triggered by radiation-induced extracellular vesicles
5: TRT immunostimulatory effects
6: Concluding remarks
Acknowledgments
References
Chapter Five: Opportunities and challenges of low-dose radiation to enable immunotherapy efficacy
Abstract
1: Introduction
2: Immunotherapy in combination with high dose irradiation
3: Is high dose irradiation immune suppressive?
4: Low dose irradiation for tumor immune reprogramming
5: Development and clinical applications of LDRT combined with immunotherapy
6: Conclusions and future directions
References
Chapter Six: Radiation therapy-activated nanoparticle and immunotherapy: The next milestone in oncology?
Abstract
1: Cancer treatment modalities and their respective action mechanisms
2: Current combinations of these therapies including RT
3: Interest and strategies to develop RT/NP/IT combination
4: Conclusion
References
Chapter Seven: Relationship between the tumor microenvironment and the efficacy of the combination of radiotherapy and immunotherapy
Abstract
1: Introduction
2: Radiotherapy
3: Cancer immunotherapy
4: The rationale for combination immune checkpoint blockade and radiotherapy
5: Preclinical models combining immunotherapy and radiotherapy
6: Clinical trials combining immunotherapy and radiotherapy
7: Conclusion
Conflict of interest
References
Chapter Eight: Recent advances in targeting myeloid-derived suppressor cells and their applications to radiotherapy
Abstract
Research Highlights
1: Introduction
2: Biological characteristics of MDSCs
3: DDSs mechanisms of actions
4: Conclusion and prospect
References

Lorenzo Galluzzi

Lorenzo Galluzzi is Assistant Professor of Cell Biology in Radiation Oncology at the Department of Radiation Oncology of the Weill Cornell Medical College, Honorary Assistant Professor Adjunct with the Department of Dermatology of the Yale School of Medicine, Honorary Associate Professor with the Faculty of Medicine of the University of Paris, and Faculty Member with the Graduate School of Biomedical Sciences and Biotechnology of the University of Ferrara, the Graduate School of Pharmacological Sciences of the University of Padova, and the Graduate School of Network Oncology and Precision Medicine of the University of Rome “La Sapienza”. Moreover, he is Associate Director of the European Academy for Tumor Immunology and Founding Member of the European Research Institute for Integrated Cellular Pathology. Galluzzi is best known for major experimental and conceptual contributions to the fields of cell death, autophagy, tumor metabolism and tumor immunology. He has published over 450 articles in international peer-reviewed journals and is the Editor-in-Chief of four journals: OncoImmunology (which he co-founded in 2011), International Review of Cell and Molecular Biology, Methods in Cell biology, and Molecular and Cellular Oncology (which he co-founded in 2013). Additionally, he serves as Founding Editor for Microbial Cell and Cell Stress, and Associate Editor for Cell Death and Disease, Pharmacological Research and iScience.

Affiliations and expertise

Assistant Professor of Cell Biology in Radiation Oncology, Department of Radiation Oncology, Weill Cornell Medical College, NY, USA

Celine Mirjolet

Dr. Céline Mirjolet is a radiobiologist with in-depth knowledge of the impact of radiotherapy fractionation on the radiation-induced immune response and on the effectiveness of the radiotherapy and immunotherapy combination. She obtained a doctorate in radiobiology at the anti-cancer center of Nancy (France). She then moved to Brussels at the University of Belgium to study epigenetic mechanisms in transcriptional activity and cancer. For ten years, she has been working in the radiotherapy department of the Dijon cancer center in close collaboration with clinicians and physicists to develop translational research projects on the combination of immunotherapy and radiotherapy. She leads the preclinical research team in radiotherapy and radiobiology and her programs focus on the validation of preclinical concepts leading to the design of clinical trials.

Affiliations and expertise

Radiobiologist, CGFL Dijon, France